Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

With solo travel bigger than ever, Globus and Cosmos have hopped on the trend with Globus completely waiving the single supplement fee off select Globus Escapes Europe tours, while Cosmos is offering ...

StockNews.com upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a buy rating in a research ...

Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the ...

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth.

Quarterly Net Profit at Rs. 0.72 crore in December 2024 down 98.38% from Rs. 44.54 crore in December 2023. EBITDA stands at ...

State of Alaska Department of Revenue reduced its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.2% ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus vows to take "advisor support to a whole new level" with road shows, executive summits and fam trips, highlighting the ...